Cargando…

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bain, C., Merrouche, Y., Puisieux, I., Blay, J. Y., Negrier, S., Bonadona, V., Lasset, C., Lanier, F., Duc, A., Gebuhrer, L., Philip, T., Favrot, M. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063266/ https://www.ncbi.nlm.nih.gov/pubmed/9010039

Ejemplares similares

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.
por: Philip, T., et al.
Publicado: (1993)

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
por: Négrier, S., et al.
Publicado: (1992)

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994)

Pretreatment serum CRP and response to interleukin 2.
por: Blay, J. Y., et al.
Publicado: (1994)

Renal cell carcinoma induces interleukin 10 and prostaglandin E(2) production by monocytes
por: Ménétrier-Caux, C, et al.
Publicado: (1999)

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2003)

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype
por: Grelier, G, et al.
Publicado: (2009)

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
por: Rossi, J-F, et al.
Publicado: (2010)

Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.
por: Combaret, V., et al.
Publicado: (1997)

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.
por: Blay, J. Y., et al.
Publicado: (1993)

The Interleukin-17 Family of Cytokines in Breast Cancer
por: Fabre, Joseph Antoine Salvator, et al.
Publicado: (2018)

Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.
por: Banks, R. E., et al.
Publicado: (1997)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

State-of-the-art treatment of metastatic renal cell carcinoma
por: Heng, D.Y.C., et al.
Publicado: (2009)

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
por: Geertsen, P F, et al.
Publicado: (2004)

Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study
por: Denis-Laroque, Laurie, et al.
Publicado: (2021)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)
por: Bugat, R, et al.
Publicado: (2003)

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.
por: Stouthard, J. M., et al.
Publicado: (1996)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
por: Proskorovsky, Irina, et al.
Publicado: (2018)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma.
por: Goepel, J. R., et al.
Publicado: (1991)

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
por: Ahmed, F. Y., et al.
Publicado: (1996)

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
por: Jobard, Elodie, et al.
Publicado: (2015)

Metastatic renal cell carcinoma in a meningioma: a case report.
por: Han, H. S., et al.
Publicado: (2000)

Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor–Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching
por: Kosmoliaptsis, V., et al.
Publicado: (2016)

Interpreting overall survival results when progression-free survival benefits exist in today’s oncology landscape: a metastatic renal cell carcinoma case study
por: Tang, Yiyun, et al.
Publicado: (2014)

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
por: Achkar, Tala, et al.
Publicado: (2017)

Association of end‐stage renal disease with HLA phenotypes and panel reactive antibodies in patients awaiting renal transplantation in Hunan Province
por: Long, Lu, et al.
Publicado: (2022)

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
por: Cella, David, et al.
Publicado: (2014)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma
por: Pachella, Laura A., et al.
Publicado: (2015)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

A genomic perspective on HLA evolution
por: Meyer, Diogo, et al.
Publicado: (2017)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β
por: Ullah, Matti, et al.
Publicado: (2019)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_84059o8va1l64ms2f6ikhtr7pi